Sandoz, Accord Confirm First US Aubagio Generics, As Settlement Day Arrives
Accord’s Product ‘Is Ready To Ship,’ Dozen ANDA Sponsors In Place To Launch
Viatris’ Mylan and Teva are among firms holding approved ANDAs for generic Aubagio, as the product falls to generic competition in the US.
You may also be interested in...
After a couple of years of heavy downwards pressure on US generics prices, prominent off-patent companies have pointed to a change in the pricing environment as several factors combine to reduce price erosion. Meanwhile, some firms are benefiting from first generic launches as others exit the market altogether, while injectables shortages continue to loom large.
Generics Bulletin previews the most notable and anticipated events for August 2023.
The French firm’s ex-blockbuster multiple sclerosis drug, Aubagio, saw sales more than halve as generics made their mark, prompting the firm to tout recent developments for two pipeline contenders for the disease.